PLPatrícia Lordêlo

Patrícia Lordêlo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrícia Lordêlo has a total of 188 co-authors. Here are the top co-authors by number of shared publications:

  • Alcina Teles

    Patricia Lordelo Institute (IPL)

    11 shared publications
  • Ubirajara Barroso

    11 shared publications
  • Ubirajara Barroso

    Universidade Federal da Bahia, Salvador, Brazil

    9 shared publications
  • Cristina Brasil

    Bahiana School of Medicine and Public Health

    8 shared publications
  • Maria Luiza Veiga

    Division of Pediatric Urology, Department of Urology, Bahia School of Medicine, Salvador, Bahia, Brazil; Divisions of Urology, Departments of Surgery, Federal University of Juiz de Fora and School of Health and Medical Sciences of Juiz de Fora, Juiz de Fora (LFdO, JMBN), Minas Gerais, Brazil

    5 shared publications
  • Maria Clara Pavie

    Pelvic Floor Care Center (CAAP), Medicine and Human Health at the Bahiana School of Medicine and Public Health, Salvador, Salvador, Brazil

    4 shared publications

Latest Publications

  • Open Access

    Mental health in the virtual world: Are we ready for the metaverse era?

    by Tuffy Mamede, Patrícia Lordêlo

    The advent of the metaverse, including virtual reality, augmented reality, and artificial intelligence, is an undeniable issue that health care scientists need to update. It influences all fields of knowledge, interpersonal relationships, and health. Regarding mental health since the post-coronavirus disease 2019 pandemic, it is necessary to consider and understand the potential, possibilities, weaknesses, and consequences arising from and provided by this new scenario. Due to the increasing need for mental health monitoring and care, mental health treatments require in-depth training and preparation to achieve the maximum use of the metaverse advantages and possibilities. Currently, very little is known about the effectiveness of remote mental health treatment, but it is certainly suggested that accessibility and the characteristics associated with the use of metaverse technologies may represent new horizons for accessibility and approach tools, as long as more studies are carried out and more evidence is collected to develop accurate guidelines, safe training, solve ethical concerns, and overcome limitations.


  • Open Access

    Radiofrequency in the Treatment of Urinary Incontinence of Female Stress: A Pilot Randomized Clinical Trial

    by Cristina Brasil, Danielle Sodré, Amanda Lemos, João Coutinho, Mauricio Vieira, Tuffy Mamede, Alcina Teles, Patricia Lordelo

    Radiofrequency (RF) is a new therapeutic option that may aid one of the pathophysiological mechanisms of stress urinary incontinence (SUI), which is a decrease in collagen in the urethral walls. This study aimed to verify the clinical response to nonablative RF treatment for SUI in women. This randomized clinical trial included women with SUI, randomized into two groups: the RF group (RG), which had five sessions of outpatient kinesiotherapy associated with monopolar nonablative RF, in the external urethral meatus (39–41°C) for 2 min, and the control group (CG), which followed the same protocol, except the RF was replaced with heated glycerin. All participants performed home exercises. Outcomes were assessed one week after treatment completion. The RG and CG had 13 and 9 women, respectively. The median reduced from 7.0 (4.5–14.5) to 1.0 (0.0–4.0) in the RG. In addition, a reduction in urinary loss was observed through a voiding diary, an increase in strength, endurance, resistance, and speed of the PERFECT scheme. There was a reduction in urinary loss in grams in women who underwent nonablative RF in the external urethral meatus.


  • Open Access

    Novel Nonablative Radiofrequency Approach for the Treatment of Anal Incontinence: A Phase 1 Clinical Trial

    by Patrícia Lordêlo, Juliana Barros, Claudia Liony, Cristiane Maria Carvalho C Dias, Janine Ferreira, Priscila G Januário, Luana N Matos, Camila O Muniz, Laizza S Silva, Cristina Brasil

    Objective: We aimed to describe the action, impact on quality of life, and side effects of perianal nonablative radiofrequency (RF) application in the treatment of anal incontinence (AI) in women. Methods: This was a pilot, randomized clinical trial conducted between January and October 2016. We enrolled women who consecutively attended the Attention Center of the Pelvic Floor (CAAP) with complaints of AI for more than six months. Nonablative RF was applied to the perianal region of the participants using Spectra G2 (Tonederm®, Rio Grande do Sul, Brazil). The reduced or complete elimination of the need for protective undergarments (diapers and absorbents) was considered a partial therapeutic response. Results: Nine participants reported treatment satisfaction, while one reported dissatisfaction with the nonablative RF treatment of AI based on the Likert scale. No patient interrupted treatment sessions because of adverse effects, although adverse effects occurred in six participants. However, the clinical and physical examination of the participants with burning sensations showed no hyperemia or mucosal lesions. Conclusions: This study showed a promising reduction of fecal loss, participant satisfaction with treatment, and improved lifestyle, behavior, and depression symptoms with minimal adverse effects.


  • Open Access

    Intravaginal nonablative radiofrequency in the treatment of genitourinary syndrome of menopause symptoms: a single-arm pilot study

    by Cintia Pinheiro, Teresa Costa, Raira Amorim de Jesus, Raquel Campos, Rosa Brim, Alcina Teles, Andrea Vilas Boas, Patrícia Lordêlo

    Background: Genitourinary syndrome of menopause (GSM) involves vaginal dryness (VD), pain during sexual activity (SAPain), vaginal itching (VI), burning, pain, and symptoms in the urinary organs. Non-ablative radiofrequency (RF) is a type of current with electromagnetic waves with a thermal effect that generates an acute inflammatory process with consequent neocolagenesis and neoelastogenesis. We aimed to describe the clinical response to VD, SAPain, vaginal laxity (VL), VI, burning sensation, pain in the vaginal opening, urinary incontinence, sexual dysfunction, cytological changes, and adverse effects of non-ablative RF in patients with GSM. Methods: This single-arm pilot study included 11 women diagnosed with GSM with established menopause. Patients with hormone replacement initiation for six months, who used a pacemaker, or had metals in the pelvic region, were excluded. Subjective measures (numeric rating scale of symptoms, Vaginal Health Index-VHI) and objective measures (vaginal maturation index-VMI, vaginal pH, sexual function by the FSFI, and urinary function by the ICIQ-SF) were used. A Likert scale measures the degree of satisfaction with the treatment. Five sessions of monopolar non-ablative RF (41°C) were performed with an interval of one week between each application. The entire evaluation was performed before treatment (T0), one month (T1), and three months (T2) after treatment. Adverse effects were assessed during treatment and at T1 and T2. Results: The symptoms and/or signs were reduced after treatment in most patients (T1/T2, respectively): VD 90.9%/81.8%, SAPain 83.3%/66.7, VL 100%/100%, VI 100%/100%, burning 75%/87.5%, pain 75%/75%, and VHI 90.9%/81.9%. Most patients did not show changes in VMI (54.5%) and pH (63.6%) at T1, but there was an improvement in VMI in most patients (54.5%) at T2. Nine patients were satisfied, and two were very satisfied at T1. The treatment was well tolerated, and no adverse effects were observed. There was an improvement in sexual function (72.7%) and urinary function (66.7% in T1 and 83.3% in T2). Conclusion: Intravaginal RF reduced the clinical symptoms of GSM in most patients, especially during T1, and women reported satisfaction with treatment. The technique showed no adverse effects, and there were positive effects on sexual and urinary function. Trial registration This research was registered at clinicaltrial.gov (NCT03506594) and complete registration date was posted on April 24, 2018.


  • Open Access

    Blue LED as a new treatment to vaginal stenosis due pelvic radiotherapy: Two case reports

    by Daniela Barros, Cecília Alvares, Teresa Alencar, Priscila Baqueiro, Augusto Marianno, Rafael Alves, Juliana Lenzi, Laura Ferreira Rezende, Patricia Lordelo

    Currently, the advancement cancer treatment technology improves overall survival, however, adverse events are still a challenge for health professional. Genitourinary syndrome of menopause and vaginal stenosis are conditions that impact the quality of life of patients undergoing radiotherapy. We present two such cases in patients with previous cervical and endometrial cancer. These conditions were handled with an innovative method using an energy-based device with blue light emitting diode for concomitant vaginal and vulvar irradiation. Positive impact in clinical findings, cytologic changes, and referred symptoms were documented. One patient diagnosed with vaginal severe vaginal stenosis with previous cervix cancer treatment and other patient diagnosed with mild stenosis with severe dyspareunia and recent endometrium cancer treatment were considered for vulvovaginal treatment with weekly blue led device and closely evaluated with repeated validated questionnaires and cytological samples. This innovative technique showed an improvement in all areas of the examiner's criteria, the cytological criteria, and most bothered symptoms.


  • Light emitting diode for the treatment of genitourinary syndrome of menopause in breast cancer survivors: study protocol for a double blinded trial

    by Daniela Barros, Maria Clara Pavie, Roseny Ferreira, Cecilia Alvares, Teresa Costa, Priscila Baqueiro, Ananda Machado Rego, Emylle Anunciação, Augusto Mariano, Julia Lopes, et al.

    Background: Genitourinary Syndrome of Menopause (GSM) after breast cancer are secondary to many mechanisms such long-term side effects of cancer treatment. Light-Emitting Diode (LED) is a treatment aimed at improving vaginal epithelial tissue. This study will aim to analyze the effects of 405 nm LED on GSM of breast cancer survivors.Methods: This double-blind, randomized clinical trial will be conducted with breast cancer survivors aged 18-65 years, diagnosed with GSM, with at least one sign and one symptom of GSM and vaginal pH≥5 or proven cytologic hypotrophy or atrophy. Pregnant women, those who received hormone replacement within the prior 6 months, with active vaginal infection, impaired comprehension, neurological disease, and progression to metastatic disease during the protocol, will be excluded. LED will be applied intravaginally with gel heated to 38ºC. Each 5/weekly session will last 8 minutes, concurrent with pelvic floor muscle kinesiotherapy. The control group will be treated with the same protocol with LED device turned off. Response will be assessed with the Vaginal Maturation Index analysis, vaginal cytology, and questionnaires to evaluate urinary complains, sexual function, genital self-image and quality of life. Satisfaction will be assessed using a Visual Analog and Likert scale. Measurements will be performed pre-treatment, post-treatment week-3, and month-2 and 3.Conclusions: We aim to identify the benefits of LED for breast cancer survivors with GSM.Trial registration: Clinical trials registration number NCT03833726-version 2.0, July 28, 2019.

  • Open Access

    A Standardized Evaluation Method for Assessing Patients With Genital Dyschromia

    by Rafael Alves, Tâmara Gomes, Priscilla Baqueiro, Patrícia Fróes Meyer, Daniela Barros, Antonio Schiattarella, Michele Fichera, Laizza Silva, Brenda Ianca de Santana, Patrícia Lordelo

    The population's ever-growing concern with genital aesthetic dysfunctions reflects an increasing demand in the field of intimate aesthetics. For this reason, as well as the lack of a standardized evaluation, this paper aims to develop a form that facilitates the initial investigation of aesthetic genital dysfunctions. An evaluation form for female and male genital dyschromia was developed between July and November 2018. Following initial development, the form was evaluated for quality and was updated by a panel of specialists (a psychologist, two pelvic dysfunction physiotherapists, and two dermato-functional physiotherapists) via email and through a content validity questionnaire. The face validity of the form was assessed by five physiotherapy and medical students who were randomly selected. The students answered a questionnaire evaluating the proposed form. The reliability of the form was established through the test-retest procedure by evaluating its reproducibility over time. The “Genital Dyschromia Evaluation Form'' (composed of identification, anamnesis, and physical examination sections) was approved by the specialist panel. They suggested questions to be added in the anamnesis (dermatological lesions or fungal and bacterial infections) and physical examination (hyperemia, edema in the perianal and internal thigh region) sections. As for the image analysis, an increase in quality, resolution, and sharpness was suggested. Lastly, for the cutaneous phototype evaluation, the DoctorSkinFototipo® digital analyzer device was chosen since it is small, portable, easily positioned on the genital area, and can be readily cleaned between patients. The “Genital Dyschromia Evaluation Form” is a questionnaire approved by specialists and could represent a suitable option for health professionals.


  • Open Access

    Intravaginal Non-Ablative Radiofrequency In The Treatment Of Genitourinary Syndrome Of Menopausesymptoms: A Phase I Clinical Trial

    by Cintia Pinheiro, Teresa Alencar, Raira Amorim, Raquel Campos, Rosa Brim, Alcina Teles, Andrea Queiroz, Patrícia Lordelo

    Background: Genitourinary Syndrome of Menopause (GSM) involves vaginal dryness, dyspareunia, itching, burning, pain, and also symptoms in urinary organs. Non-ablative radiofrequency (RF) is a type of current with electromagnetic waves with the thermal effect that generates an acute inflammatory process with consequent neocolagenesis and neoelastogenesis. We aimed to describe the clinical response, cytological changes, and adverse effects of applying nonablative RF in patients with GSM and to assess sexual and urinary function after treatment. Methods: This is a pilot study with 11 women diagnosed with GSM with established menopause. Patients with hormone replacement initiation less than six months, who used a pacemaker or had metals in the pelvic region, were excluded. Subjective measures (Visual Numerical Scale-VNS of symptoms, Vaginal Health Index-VHI) and objective measures (Vaginal Maturation Index-VMI and vaginal pH) were used. Sexual function was assessed by the FSFI, and the ICIQ-SF measured the impact on urinary function. A Likert scale measured the degree of satisfaction with the treatment. Five sessions of monopolar non-ablative RF (41 °C) were performed with an interval of one week between each application. The entire evaluation was performed before treatment (T0), one month (T1), and three months (T2) after treatment. Adverse effects were assessed weekly. Results: There was a reduction in symptoms after treatment in most patients (T1/T2, respectively): vaginal dryness 90.9%/81.8%, dyspareunia 83.3%/66.7, vaginal laxity 100%/100%, pruritus 100%/100%, burning 75%/87.5%, pain 75%/75%, and in VHI 90.9%/81.9%. Most patients did not show changes in VMI (54.5%) and pH (63.6%) at T1, but there was an improvement in VMI in most patients (54.5%) at T2. Nine patients were satisfied and two were very satisfied at T1. The treatment was well tolerated and no adverse effects were observed. There was an improvement in sexual function in 72.7% and in urinary function in 66.7% in T1 and 83.3% in T2. Conclusion: Intravaginal RF reduced the clinical signs and symptoms of GSM and women reported satisfaction with treatment. The technique showed no adverse effects and there were positive effects on sexual and urinary function. Trial registration: This research was registered at clinicaltrial.gov (NCT03506594) and complete registration date (first date posted) April 24, 2018.

  • Gynecological cancers and urinary dysfunction: a comparison between endometrial cancer and other gynecological malignancies

    by George A. Vilos, Enrique Reyes-Muñoz, Gaetano Riemma, Ilker Kahramanoglu, Li-Te Lin, Benito Chiofalo, Patricia Lordelo, Luigi DELLA Corte, Amerigo Vitagliano, Gaetano Valenti

    Gynecological cancers and urinary dysfunction: a comparison between endometrial cancer and other gynecological malignancies - Minerva Medica 2021 February;112(1):96-110 - Minerva Medica - Journals


  • Relationship of Body Composition and Urinary Incontinence in Women: A Cross-Sectional Case-Control Study

    by Roseny Ferreira, Joselita Sacramento, Cristina Msc Brasil, Cristiane Dias, Clarcson Plácido, Carina Oliveira, Alina Feitosa, Priscila Januário, Michele Fichera, Patricia Lordelo

    Objective: To describe the profile of segmental body composition through the bioelectrical impedance analysis (BIA) method in continent and incontinent women and analyze the association between overweight/obesity and urinary incontinence (UI). Methods: This was a cross-sectional case-control study that included women aged between 20 and 65 years, who were not pregnant, were outside of their menstrual period, without neurological, psychiatric, orthopedic, or cardiac comorbidities. The presence of UI was verified using the International Consultation on Incontinence Questionnaire—Short Form. Segmental body composition was assessed with BIA. The independent Student t test was used to compare body composition means between groups, and multivariate logistic regression was used to test the association between body composition and UI. Results: The study included 62 women with a mean age of 34.4 ± 11.6 years, of whom 27 (43.5%) had UI. Of these, 15 (55.6%) were nulliparous and had a body mass index of 25.1 ± 4.2 kg/m 2 , similar to that of continent women, who had a body mass index of 23.6 ± 3.9 kg/m 2 ( P =0.16). The sociodemographic and obstetric data were similar among continent and incontinent women. With respect to the parameters of segmental body fat, visceral fat, and waist circumference, incontinent women presented higher values than the continent group. In the final multivariate analysis model, women with high levels of visceral fat had a 1.13-times higher likelihood of presenting UI. Conclusions: In adult women, there is an association between the level of visceral fat assessed by BIA and complaints of urinary loss, being more evident in overweight and obese women.